These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 37130728)

  • 1. Association of serum neurofilament light with microglial activation in multiple sclerosis.
    Saraste M; Matilainen M; Vuorimaa A; Laaksonen S; Sucksdorff M; Leppert D; Kuhle J; Airas L
    J Neurol Neurosurg Psychiatry; 2023 Sep; 94(9):698-706. PubMed ID: 37130728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vivo Detection of Diffuse Inflammation in Secondary Progressive Multiple Sclerosis Using PET Imaging and the Radioligand ¹¹C-PK11195.
    Rissanen E; Tuisku J; Rokka J; Paavilainen T; Parkkola R; Rinne JO; Airas L
    J Nucl Med; 2014 Jun; 55(6):939-44. PubMed ID: 24711650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natalizumab treatment reduces microglial activation in the white matter of the MS brain.
    Sucksdorff M; Tuisku J; Matilainen M; Vuorimaa A; Smith S; Keitilä J; Rokka J; Parkkola R; Nylund M; Rinne J; Rissanen E; Airas L
    Neurol Neuroimmunol Neuroinflamm; 2019 Jul; 6(4):e574. PubMed ID: 31355310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal stability of progression-related microglial activity during teriflunomide treatment in patients with multiple sclerosis.
    Lehto J; Nylund M; Matilainen M; Sucksdorff M; Vuorimaa A; Rajander J; Wahlroos S; Hariri P; Airas L
    Eur J Neurol; 2023 Aug; 30(8):2365-2375. PubMed ID: 37154404
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Datta G; Colasanti A; Kalk N; Owen D; Scott G; Rabiner EA; Gunn RN; Lingford-Hughes A; Malik O; Ciccarelli O; Nicholas R; Nei L; Battaglini M; De Stefano N; Matthews PM
    J Nucl Med; 2017 Sep; 58(9):1477-1482. PubMed ID: 28302760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A quantitative neuropathological assessment of translocator protein expression in multiple sclerosis.
    Nutma E; Stephenson JA; Gorter RP; de Bruin J; Boucherie DM; Donat CK; Breur M; van der Valk P; Matthews PM; Owen DR; Amor S
    Brain; 2019 Nov; 142(11):3440-3455. PubMed ID: 31578541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Innate immune cells and myelin profile in multiple sclerosis: a multi-tracer PET/MR study.
    Pitombeira MS; Koole M; Campanholo KR; Souza AM; Duran FLS; Solla DJF; Mendes MF; Pereira SLA; Rimkus CM; Busatto GF; Callegaro D; Buchpiguel CA; de Paula Faria D
    Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4551-4566. PubMed ID: 35838758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis.
    Sucksdorff M; Matilainen M; Tuisku J; Polvinen E; Vuorimaa A; Rokka J; Nylund M; Rissanen E; Airas L
    Brain; 2020 Dec; 143(11):3318-3330. PubMed ID: 33006604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early prognosticators of later TSPO-PET-measurable microglial activation in multiple sclerosis.
    Laaksonen S; Saraste M; Sucksdorff M; Nylund M; Vuorimaa A; Matilainen M; Heikkinen J; Airas L
    Mult Scler Relat Disord; 2023 Jul; 75():104755. PubMed ID: 37216883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the Effect of Fingolimod Treatment on Microglial Activation Using Serial PET Imaging in Multiple Sclerosis.
    Sucksdorff M; Rissanen E; Tuisku J; Nuutinen S; Paavilainen T; Rokka J; Rinne J; Airas L
    J Nucl Med; 2017 Oct; 58(10):1646-1651. PubMed ID: 28336784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between microglial activation and serum kynurenine pathway metabolites in multiple sclerosis patients.
    Saraste M; Matilainen M; Rajda C; Galla Z; Sucksdorff M; Vécsei L; Airas L
    Mult Scler Relat Disord; 2022 Mar; 59():103667. PubMed ID: 35151985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotyping of multiple sclerosis lesions according to innate immune cell activation using 18 kDa translocator protein-PET.
    Nylund M; Sucksdorff M; Matilainen M; Polvinen E; Tuisku J; Airas L
    Brain Commun; 2022 Feb; 4(1):fcab301. PubMed ID: 34993478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lower cerebral arterial blood flow is associated with greater serum neurofilament light chain levels in multiple sclerosis patients.
    Jakimovski D; Gibney BL; Marr K; Ramasamy DP; Dwyer MG; Bergsland N; Weinstock-Guttman B; Ramanathan M; Zivadinov R
    Eur J Neurol; 2022 Aug; 29(8):2299-2308. PubMed ID: 35474598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insights into disseminated MS brain pathology with multimodal diffusion tensor and PET imaging.
    Bezukladova S; Tuisku J; Matilainen M; Vuorimaa A; Nylund M; Smith S; Sucksdorff M; Mohammadian M; Saunavaara V; Laaksonen S; Rokka J; Rinne JO; Rissanen E; Airas L
    Neurol Neuroimmunol Neuroinflamm; 2020 May; 7(3):. PubMed ID: 32123046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated microglia do not increase 18 kDa translocator protein (TSPO) expression in the multiple sclerosis brain.
    Nutma E; Gebro E; Marzin MC; van der Valk P; Matthews PM; Owen DR; Amor S
    Glia; 2021 Oct; 69(10):2447-2458. PubMed ID: 34145928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum neurofilament light is a sensitive biomarker that reflects grey matter volume in Japanese patients with multiple sclerosis.
    Fujimori J; Nakashima I
    J Neurol Sci; 2021 Aug; 427():117528. PubMed ID: 34098375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurofilament light chains in serum as biomarkers of axonal damage in early MS lesions: a histological-serological correlative study.
    Dietmann AS; Kruse N; Stork L; Gloth M; Brück W; Metz I
    J Neurol; 2023 Mar; 270(3):1416-1429. PubMed ID: 36372867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.
    Siller N; Kuhle J; Muthuraman M; Barro C; Uphaus T; Groppa S; Kappos L; Zipp F; Bittner S
    Mult Scler; 2019 Apr; 25(5):678-686. PubMed ID: 29542376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study.
    Jakimovski D; Kuhle J; Ramanathan M; Barro C; Tomic D; Hagemeier J; Kropshofer H; Bergsland N; Leppert D; Dwyer MG; Michalak Z; Benedict RHB; Weinstock-Guttman B; Zivadinov R
    Ann Clin Transl Neurol; 2019 Sep; 6(9):1757-1770. PubMed ID: 31437387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of cortico-meningeal translocator protein expression in multiple sclerosis.
    Herranz E; Treaba CA; Barletta VT; Mehndiratta A; Ouellette R; Sloane JA; Ionete C; Babu S; Mastantuono M; Magon S; Loggia ML; Makary MM; Hooker JM; Catana C; Kinkel RP; Nicholas R; Klawiter EC; Magliozzi R; Mainero C
    Brain; 2024 Jul; 147(7):2566-2578. PubMed ID: 38289855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.